Show simple item record

dc.contributor.authorTravé-Asensio, Sergi
dc.contributor.authorTort-Miró, Aida
dc.contributor.authorPinheiro, Silvana
dc.contributor.authorGarcia-Fruitos, Elena
dc.contributor.authorArís, Anna
dc.contributor.authorZamora, William J.
dc.contributor.otherProducció Animalca
dc.date.accessioned2026-01-29T18:56:38Z
dc.date.available2026-01-29T18:56:38Z
dc.date.issued2025-09-23
dc.identifier.issn1751-7915ca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/5013
dc.description.abstractHost defence peptides (HDPs) represent a valuable class of antimicrobial agents with the potential to address the growing threat of antimicrobial resistance (AMR). Here, we have studied recombinant constructs based on a combination of HDPs fused to the GFP protein and multidomain proteins combining three or four HDPs in a single polypeptide, referred to as first and second generation antimicrobials, respectively. These recombinant peptides were tested against Gram-positive and Gram-negative bacteria associated with healthcare infections. In addition, in silico studies provided insight into the antimicrobial structure–activity relationships of these biomolecules. For the first generation of antimicrobials, amphipathicity mainly explains the average antimicrobial activity against the Gram-positive strains. In the case of the Gram-negative bacteria, it depends on the quantity and the exposed area of the Ser and Thr amino acids. For the second generation of antimicrobials, the order of domains is crucial to act against Gram-positive strains, preferably by positioning the most bioactive domain against the Gram-positive pathogen at the ends.ca
dc.format.extent19ca
dc.language.isoengca
dc.publisherWileyca
dc.relation.ispartofMicrobial Biotechnologyca
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleStructure–Antimicrobial Activity Relationships of Recombinant Host Defence Peptides Against Drug-Resistant Bacteriaca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.relation.projectIDMICIU/Programa Estatal de generación del conocimiento y fortalecimiento científico y tecnológico del sistema I+D+I y Programa Estatal de I+D+I orientada a los retos de la sociedad/PID2019-107298RB-C21/ES/PRODUCCION Y VALIDACION DE FARMACOS BASADOS EN PEPTIDOS DE DEFENSA DEL HUESPED PARA EL TRATAMIENTO DEL SINDROME RESPIRATORIO BOVINO/ca
dc.subject.udc579ca
dc.identifier.doihttps://doi.org/10.1111/1751-7915.70204ca
dc.contributor.groupProducció de Remugantsca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint